BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

Rhea-AI Summary

BioStem Technologies (OTC: BSEM) launched a new placental-derived wound care line, American Amnion, at the Desert Foot conference (Dec 10-13, 2025) with Hands-On Workshops on Dec 11.

Products include American Amnion AC (full thickness DHACM with intermediate layer) and American Amnion (DHAM with intermediate layer), both preserved with BioRetain technology.

Clinical highlights cited: a randomized trial showing 53% wound closure vs 31% for standard care, a retrospective study reporting 14% faster time to closure and 27% fewer applications, and a noted 50% rise in placental product use in the VA over five years.

Positive

• Randomized trial: wound closure 53% vs 31% (BioRetain product)
• Comparative study: 14% reduction in time to closure
• Comparative study: 27% fewer applications to achieve closure
• Targeted market: 50% increase in VA placental-product use (5 years)
• Product launch: debut at Desert Foot conference with six workshops Dec 11

Negative

• None.

News Market Reaction

+6.27%

1 alert

+6.27% News Effect

On the day this news was published, BSEM gained 6.27%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Wound closure rate: 53% Standard of care closure: 31% Time to closure reduction: 14% +2 more

5 metrics

Wound closure rate 53% Patients treated with BioRetain-preserved full thickness amniochorion (BR-AC) in randomized trial

Standard of care closure 31% Patients treated with standard of care in same randomized trial

Time to closure reduction 14% Reduction in time to closure vs leading competitor in retrospective study

Fewer applications needed 27% Fewer applications required vs leading competitor in retrospective study

VA placental-product use growth 50% Increase in placental-based product use in VA system over last five years

Market Reality Check

Price: $6.17 Vol: Volume 28,787 is below 20...

low vol

$6.17 Last Close

Volume Volume 28,787 is below 20-day average of 70,156 (relative volume 0.41x). low

Technical Shares at $4.27 are trading below the 200-day MA of $9.03, well under the 52-week high of $19.28.

Peers on Argus

BSEM gained 6.27% while key biotech peers like MSCLF (-4%), ACHFF (-3.72%), AURX...

BSEM gained 6.27% while key biotech peers like MSCLF (-4%), ACHFF (-3.72%), AURX (-2.33%), and NRXBF (-1.91%) were down, indicating a stock-specific move rather than a sector-wide shift.

Historical Context

5 past events · Latest: Nov 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 25	Market access expansion	Positive	+5.0%	Florida Medicaid added VENDAJE products, expanding coverage to 13 state programs.
Nov 13	Earnings update	Positive	-4.0%	Profitable Q3 2025 with revenue, EBITDA, and cash strength highlighted.
Nov 13	Financial restatement	Neutral	-4.0%	Restated statements reclassifying fees to contra revenue without changing earnings or cash.
Nov 05	Reimbursement commentary	Neutral	-5.6%	Commentary on CY 2026 CMS rule with lower-than-sought reimbursement but robust margins expected.
Nov 05	HQ expansion	Positive	+2.0%	Purchase of four-acre parcel for future HQ with job-creation incentives.

Pattern Detected

Recent news has often seen mixed or negative price reactions, even when updates were operationally or strategically constructive.

Recent Company History

Over the last several weeks, BioStem reported multiple developments, including expanded Medicaid access for VENDAJE products, Q3 2025 profitability with $10.5M net revenue, and restated financials to support an independent audit and potential uplist. It also commented on CMS’s CY 2026 reimbursement rule and purchased a four-acre site for a future headquarters. Today’s American Amnion launch builds on this trajectory of commercialization, reimbursement positioning, and infrastructure expansion in advanced wound care.

Market Pulse Summary

The stock moved +6.3% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +6.3% in the session following this news. A strong positive reaction aligns with the constructive tone of this product launch, as BSEM traded up 6.27% while most peers declined. The company had already highlighted clinical evidence and VA-focused initiatives, and American Amnion extends that strategy into a defined veteran wound-care need. However, shares remained well below the 200-day MA of $9.03 and 77.85% under the 52-week high, underscoring ongoing execution and sentiment risks.

Key Terms

allograft, dehydrated human amnion and chorion membrane (DHACM), dehydrated human amnion membrane (DHAM), homologous use, +1 more

5 terms

allograft medical

"American Amnion AC is a human connective tissue allograft comprised of full thickness"

Tissue taken from one person and transplanted into another to repair or replace damaged body parts, such as bone, skin, or heart valves. For investors, allografts matter because their use involves manufacturing standards, supply and safety controls, regulatory approvals, and reimbursement rules that can affect sales, liability and growth for companies that process, store or sell these biological materials — similar to how sourcing and quality control of key parts affect a manufacturer’s business.

dehydrated human amnion and chorion membrane (DHACM) medical

"allograft comprised of full thickness dehydrated human amnion and chorion membrane (DHACM)"

Dehydrated human amnion and chorion membrane (dhACM) is a medical product made by processing and drying the two outer layers of a donated placenta to create a sterile tissue patch that supports wound and surgical healing. For investors, dhACM matters because it is a regulatory‑controlled, higher‑margin clinical material whose adoption, reimbursement status, manufacturing scale and safety record can directly affect a medical company's sales, costs and legal risk — think of it as a specialized spare part for the body used in surgeries and wound care.

dehydrated human amnion membrane (DHAM) medical

"American Amnion is comprised of dehydrated human amnion membrane (DHAM) also including"

Dehydrated human amnion membrane (dHAM) is a preserved layer taken from the innermost part of the placenta that acts like a natural, sterile bandage and scaffolding to help tissues heal. Investors watch dHAM because it is sold as a medical product for wound care and surgical repairs; its commercial potential depends on clinical effectiveness, regulatory approvals, supply and ethical sourcing, and how easily hospitals and insurers will adopt and pay for it.

homologous use medical

"Both are intended for homologous use as a protective covering for acute or chronic wounds"

Homologous use describes using a biological product or tissue for the same basic job it performs in the body where it came from — like using heart tissue to help heart function, not for a different organ or purpose. For investors, it matters because regulators often allow simpler, faster approval and fewer controls when a product stays within that original role, which can reduce development time, costs and commercial risk, similar to selling a tool for the task it was designed to do.

randomized controlled clinical trial medical

"In a multi-center randomized controlled clinical trial published in the International Journal"

A randomized controlled clinical trial is a medical study where participants are randomly assigned to two or more groups—typically one receiving the treatment under test and another receiving a placebo or standard care—to objectively measure whether the treatment works and is safe. For investors, these trials are the gold standard for proving a drug or device’s effectiveness, because their clear, unbiased results strongly influence regulatory approval, market adoption, and the commercial value of healthcare companies.

AI-generated analysis. Not financial advice.

Expanding its Portfolio with American Amnion to Serve the Wound Care Needs of Our Veterans

POMPANO BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today announced the launch of a new product line, American Amnion, at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference held in Phoenix, Arizona, on December 10-13, 2025.

American Amnion AC is a human connective tissue allograft comprised of full thickness dehydrated human amnion and chorion membrane (DHACM) including the intermediate layer, while American Amnion is comprised of dehydrated human amnion membrane (DHAM) also including the intermediate layer. Both are intended for homologous use as a protective covering for acute or chronic wounds and are produced using BioStem’s proprietary BioRetain^® technology, which optimizes the preservation of the native tissue’s innate structural and molecular composition.

Allografts produced with this technology have demonstrated superior clinical performance as documented in several recently published studies. In a multi-center randomized controlled clinical trial published in the International Journal of Tissue Repair (2025), McCoy et al. reported that patients treated with the BioRetain-preserved full thickness amniochorion product (referenced in the published manuscript as BR-AC) demonstrated a probability of wound closure (53%) that was almost twice that observed in patients treated with the standard of care (31%). Similarly, in a comparative retrospective study published in Health Science Reports (2024), Frykberg et al. documented that the BioRetain-preserved DHACM outperformed a leading competitor in both clinical and cost effectiveness, by demonstrating a 14% reduction in time to closure and requiring 27% fewer applications to achieve closure. 

“Veterans represent a significantly underserved population with a disproportionately high risk of chronic, non-healing wounds. The introduction of American Amnion is a meaningful step forward in advancing the standard of care for these patients,” said Jason Matuszewski, CEO and Chairman of BioStem Technologies. “The use of placental-based products has increased by 50% over the last five years in the VA system. By bringing innovative, evidence-driven solutions to market, we are not only improving outcomes and quality of life for our veterans, but also helping our clinician partners deliver more efficient, cost-effective care.”

BioStem not only supports our veterans in the clinic, but also in the community. The Company recently became the exclusive sponsor of the Florida Panthers’ Heroes Among Us program. This program publicly recognizes the contributions of a United States military veteran before every home game at the Panthers’ Amerant Bank Arena in Sunrise, FL, near the Company’s Pompano Beach global headquarters.

Experience American Amnion at The Desert Foot Conference:

• December 11^th from 10:30 am to 1:30 pm MST at one of BioStem’s six Hands-On Workshops: Superior Science that Delivers Optimal Results: Preserving the Natural Integrity in Amniotic Tissue for Advanced Wound Care.
• December 11^th from 2:30 pm to 3:00 pm MST during the Scientific Agenda: Optimizing Preservation of Inherent Properties in Placental Membranes: Impact on Clinical Outcomes in Advanced Wound Care, Wendy Weston, PhD

About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain^® processing method. BioRetain^® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE^®, VENDAJE AC^®, VENDAJE OPTIC^®, American Amnion™, and American Amnion AC™. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn.

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.

Contact BioStem Technologies, Inc.:
Website: www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Philip Trip Taylor, Gilmartin Group
E-Mail: ir@biostemtech.com

FAQ

What is BioStem Technologies announcing at the Desert Foot conference on Dec 10-13, 2025 (BSEM)?

BioStem (OTC: BSEM) is debuting the American Amnion product line and hosting Hands-On Workshops on Dec 11.

What are the clinical results cited for American Amnion (BSEM)?

A randomized trial reported 53% wound closure with the BioRetain-preserved product versus 31% for standard of care.

How does American Amnion compare on treatment efficiency and applications (BSEM)?

A retrospective study reported a 14% faster time to closure and 27% fewer applications versus a leading competitor.

Which American Amnion products did BioStem introduce and what do they contain (BSEM)?

The company introduced American Amnion AC (full thickness DHACM) and American Amnion (DHAM), both including the intermediate layer.

When and where can clinicians experience American Amnion demonstrations (BSEM)?

Hands-On Workshops are scheduled Dec 11 from 10:30 am to 1:30 pm MST, plus a scientific talk at 2:30–3:00 pm MST.

How is BioStem positioning American Amnion for veterans and VA care (BSEM)?

The company cites veterans as a focus, noting a 50% increase in placental product use in the VA over five years.